Resources

Dr Mahony will work with the UK Government to champion investment into the UK’s innovative life sciences and biotech sector, including playing a key role in the ongoing pension reforms led by Chancellor Rachel Reeves MP.

PIR International recently partnered with Closed Loop Medicine in appointing Luba Greenwood as Non-Executive Chair

OMass Therapeutics, a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlton as Chief Scientific Officer (CSO).

Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with IMU Biosciences and is pleased to announce the placements of Dr John Baker as Chief Executive Officer and Dr Jason Brown as Chief Business Officer.

We are excited to welcome the newly elected members of the BIA Board of Directors, who will bring fresh insights and expertise to help drive our mission forward. Nick Gardiner shares his perspective on the importance of these appointments and the unique value each new Director brings to the BIA.

BioPartner UK announces the appointment of Mike Fisher, PhD, VP and Head of Business Development at Oncimmune, to its Advisory Board.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, recaps the recent Women in Biotech event in Manchester, where industry leaders discussed talent attraction, female leadership, and career advancement. The panel highlighted the importance of fostering home-grown talent, supporting female role models, and offering mentorship opportunities.

The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, has appointed a new Non-Executive Director to its board, Dr Hsin Loke. 

In an ever-evolving life science industry, understanding compensation trends and having access to real-time data is not just a necessity—it's a strategic advantage. At J.Thelander Consulting, we are thrilled to announce our exclusive partnership with the BioIndustry Association (BIA).

Engitix Ltd announced the appointment of two biotech industry leaders as Scientific Advisors: Adrian S. Ray, PhD, and Scott Turner, PhD.